UNIGE document Scientific Article - Meta-analysis
previous document  unige:20856  next document
add to browser collection

Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis

Mallouk, N.
Berdague, P.
Labruyere, C.
Barazer, I.
Gris, J. C.
Laporte, S.
show hidden authors show all authors [1 - 10]
Published in Journal of Thrombosis and Haemostasis. 2010, vol. 8, no. 5, p. 923-933
Abstract BSUMMARY BACKGROUND: Previous studies have shown an important risk of cardiovascular events in patients with clopidogrel biological non-response, and data have shown considerable, unexplored heterogeneity. OBJECTIVES: To evaluate the magnitude of cardiovascular risk associated with clopidogrel non-response and to explore heterogeneity. METHODS: This was a systematic review and meta-analysis of prospective studies of patients treated with clopidogrel for symptomatic atherothrombosis, evaluated by light transmission aggregometry with ADP and monitored prospectively for clinical ischemic events. RESULTS: Fifteen studies were included, totaling 3960 patients, of whom 25% were considered to be clopidogrel non-responders. The global relative risk (RR) for recurrent ischemic events in clopidogrel non-responders was 3.5 [95% confidence interval (CI) 2.4-5.2, P < 0.0001]. The results of the different studies were heterogeneous (Cochran P = 0.01 and I(2) = 52%). The most recent studies yielded lower RRs [global RR = 2.9 (95% CI 2.3-3.8) after 2007, and global RR = 6.6 (95% CI 3.7-11.9) before 2007, P = 0.01]. Heterogeneity was present in the group of studies in which more than 10% of patients took glycoprotein (GP)IIb-IIIa inhibitors [Cochran P = 0.003 and I(2) = 70%; RR = 3.8 (95% CI 2.9-5.1)] and was absent in the other studies [Cochran P = 0.88 and I(2) = 0; RR = 2.5 (95% CI 1.7-3.6)]. The RR was significantly higher in studies using higher ADP maximal aggregation cut-offs (> 65%) for clopidogrel non-response than in studies using lower cut-offs [RR = 5.8 (95% CI 3.2-10.3) and RR = 2.9 (95% CI 2.2-3.7), respectively, P = 0.03]. CONCLUSIONS: The risk of ischemic events associated with clopidogrel non-response is now more precisely defined. The risk is heterogeneous across studies, possibly because of an interaction with GPIIb-IIIa inhibitors and the use of different cut-offs to identify non-responders.
Keywords Cardiovascular Diseases/*drug therapyHumansPlatelet Aggregation Inhibitors/*therapeutic useTiclopidine/*analogs & derivatives/therapeutic use
PMID: 20156305
Full text
Research groups Epidémiologie clinique (115)
Geneva Platelet Group (13)
(ISO format)
COMBESCURE, Christophe et al. Clinical implications of clopidogrel non-response in cardiovascular patients: a systematic review and meta-analysis. In: Journal of Thrombosis and Haemostasis, 2010, vol. 8, n° 5, p. 923-933. doi: 10.1111/j.1538-7836.2010.03809.x https://archive-ouverte.unige.ch/unige:20856

314 hits

0 download


Deposited on : 2012-05-23

Export document
Format :
Citation style :